156 related articles for article (PubMed ID: 16483640)
1. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?
Chan JK; Manuel MR; Cheung MK; Osann K; Husain A; Teng NN; Rao A; Carlson RW; Whittemore AS
Gynecol Oncol; 2006 Sep; 102(3):508-12. PubMed ID: 16483640
[TBL] [Abstract][Full Text] [Related]
2. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.
Ueda SM; Kapp DS; Cheung MK; Shin JY; Osann K; Husain A; Teng NN; Berek JS; Chan JK
Am J Obstet Gynecol; 2008 Feb; 198(2):218.e1-6. PubMed ID: 18226630
[TBL] [Abstract][Full Text] [Related]
3. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
4. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma.
Geisler JP; Sorosky JI; Duong HL; Buekers TE; Geisler MJ; Sood AK; Anderson B; Buller RE
Gynecol Oncol; 2001 Dec; 83(3):501-3. PubMed ID: 11733962
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for uterine cancer in reproductive-aged women.
Lee NK; Cheung MK; Shin JY; Husain A; Teng NN; Berek JS; Kapp DS; Osann K; Chan JK
Obstet Gynecol; 2007 Mar; 109(3):655-62. PubMed ID: 17329517
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features.
Barakat RR; Wong G; Curtin JP; Vlamis V; Hoskins WJ
Gynecol Oncol; 1994 Nov; 55(2):164-8. PubMed ID: 7959278
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
8. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.
Olawaiye AB; Rauh-Hain JA; Withiam-Leitch M; Rueda B; Goodman A; del Carmen MG
Gynecol Oncol; 2008 Sep; 110(3):293-8. PubMed ID: 18644620
[TBL] [Abstract][Full Text] [Related]
9. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant radiation therapy in stage III node-positive uterine cancer.
Schmid S; Hsu IC; Hu JM; Sherman AE; Osann K; Kapp DS; Chan JK
Gynecol Oncol; 2009 Nov; 115(2):239-43. PubMed ID: 19679341
[TBL] [Abstract][Full Text] [Related]
11. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival.
Mery CM; George S; Bertagnolli MM; Raut CP
Cancer; 2009 Sep; 115(18):4055-63. PubMed ID: 19526590
[TBL] [Abstract][Full Text] [Related]
12. Supraclavicular radiation for breast cancer does not increase the 10-year risk of stroke.
Woodward WA; Giordano SH; Duan Z; Hortobagyi GN; Buchholz TA
Cancer; 2006 Jun; 106(12):2556-62. PubMed ID: 16691617
[TBL] [Abstract][Full Text] [Related]
13. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
Bansal N; Herzog TJ; Seshan VE; Schiff PB; Burke WM; Cohen CJ; Wright JD
Obstet Gynecol; 2008 Jul; 112(1):64-70. PubMed ID: 18591309
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.
Lerner DL; Walsh CS; Cass I; Karlan BY; Li AJ
Gynecol Oncol; 2007 Jan; 104(1):91-4. PubMed ID: 16934317
[TBL] [Abstract][Full Text] [Related]
15. Association between uterine serous carcinoma and breast cancer.
Gehrig PA; Bae-Jump VL; Boggess JF; Groben PA; Fowler WC; Van Le L
Gynecol Oncol; 2004 Jul; 94(1):208-11. PubMed ID: 15262144
[TBL] [Abstract][Full Text] [Related]
16. Comparison of uterine malignancies that develop during and following tamoxifen therapy.
Ferguson SE; Soslow RA; Amsterdam A; Barakat RR
Gynecol Oncol; 2006 May; 101(2):322-6. PubMed ID: 16352333
[TBL] [Abstract][Full Text] [Related]
17. The outcomes of 27,063 women with unstaged endometrioid uterine cancer.
Chan JK; Wu H; Cheung MK; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2007 Aug; 106(2):282-8. PubMed ID: 17662377
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer.
Chan JK; Kapp DS; Cheung MK; Shin JY; Stieglitz D; Husain A; Teng NN; Berek JS; Osann K; Guo H
Am J Obstet Gynecol; 2008 Feb; 198(2):216.e1-5. PubMed ID: 18226629
[TBL] [Abstract][Full Text] [Related]
19. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
[TBL] [Abstract][Full Text] [Related]
20. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
